All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Alteogen's EYLUXVI, an aflibercept biosimilar for macular degeneration, receives European Commission marketing approval
Protein therapy, ophthalmology, biosimilar, aflibercept, macular degeneration, diabetic macular edema - Read more

Biogen's Zurzuvae receives EU approval as first oral GABA modulator for postpartum depression
Small molecule, neurological, postpartum depression, neuroactive steroid, oral therapy, rapid-acting - Read more

THE GOOD
Business Development & Partnerships

ALK, GenSci partner on house dust mite allergy immunotherapy in China, GenSci gaining exclusive rights until 2039
Licensing deal, allergy immunotherapy, commercialization, respiratory diseases - Read more

OncoZenge, UCLA collaborating on patient study for BupiZenge oral pain treatment, exploring US IND application pathway
Research collaboration, oncology, drug discovery, small molecule, regulatory - Read more

PRESENTED BY PROMOVEO HEALTH
Contract Sales Reps = Fast Deployment + Lower Cost

We've built 100+ pharma sales teams for companies of all sizes, and we can help you.

We build agile field teams that scale based on your needs - all with fast deployment + lower cost than full-time reps.

See how flexible can work - click here to learn more.

✅ More Good News ✅

THE GOOD
Clinical Trials

Regeneron's garetosmab shows 90% reduction in bone lesions in Ph3 fibrodysplasia ossificans progressiva trial
Protein therapy, rare disease, monoclonal antibody, fibrodysplasia ossificans progressiva (FOP), anti-activin A mechanism - Read more

J&J's IL-23 inhibitor icotrokinra outperforms Sotyktu in Ph3 trials for moderate to severe plaque psoriasis
Small molecule, autoimmune, oral peptide, plaque psoriasis, IL-23 inhibitor, comparative trial - Read more

UCB's BIMZELX shows sustained three-year efficacy in hidradenitis suppurativa targeting IL-17A/F in Ph3 extension
Antibody, autoimmune, monoclonal antibody, hidradenitis suppurativa, IL-17 inhibitor, inflammatory skin disease - Read more

Roivant's brepocitinib succeeds in Ph3 trial for dermatomyositis, showing significant symptom reduction over placebo
Small molecule, autoimmune, inflammatory disease, dermatomyositis, TYK2/JAK1 inhibitor, steroid-sparing - Read more

Sanofi's Ph2 dual-target nanobody brivekimig achieves 67% response in hidradenitis suppurativa trial
Antibody, autoimmune, nanobody, hidradenitis suppurativa, TNF-alpha inhibitor, OX40L inhibitor - Read more

MindRank's oral GLP-1 agonist MDR-001 achieves 10.3% weight reduction in Ph2b obesity trial
Small molecule, metabolic, GLP-1 receptor agonist, obesity, AI drug discovery, oral formulation - Read more

AstraZeneca's Saphnelo (anifrolumab) meets Ph3 endpoint for subcutaneous delivery in systemic lupus erythematosus patients
Antibody, autoimmune, monoclonal antibody, systemic lupus erythematosus, subcutaneous delivery, phase III trial - Read more

Navigator Medicines' NAV-240 shows promising Ph1 data targeting OX40L/TNFα for inflammatory disorders and autoimmune diseases
Antibody, autoimmune, bispecific antibody, inflammatory disorders, TNFα inhibitor, hidradenitis suppurativa - Read more

Ascletis presents positive Ph3 results for denifanstat, a FASN inhibitor for moderate to severe acne vulgaris
Small molecule, dermatological, FASN inhibitor, acne vulgaris, first-in-class - Read more

Eli Lilly's orforglipron outperforms Novo's Rybelsus in Ph3 head-to-head GLP-1 trial for type 2 diabetes
Small molecule, metabolic, GLP-1 receptor agonist, type 2 diabetes, oral therapy, weight loss - Read more

LEO Pharma's temtokibart shows positive Ph2b results targeting IL-22RA1 in moderate-to-severe atopic dermatitis
Monoclonal antibody, autoimmune, atopic dermatitis, IL-22RA1 inhibitor, Phase 2b trial - Read more

Eli Lilly's Mounjaro shows 2.2% A1C reduction in Ph3 trial for children with type 2 diabetes
Protein therapy, metabolic, peptide agonist, type 2 diabetes, GIP/GLP-1 receptor, pediatric patients - Read more

Novo Nordisk's oral Wegovy shows comparable weight loss to injectable in Ph3 obesity trial
Small molecule, metabolic, GLP-1 receptor agonist, obesity, oral formulation, weight loss - Read more

Skyhawk's SKY-0515 shows promising Ph1 results with 62% mHTT reduction in Huntington's disease patients
Small molecule, neurological, RNA splicing modifier, Huntington's disease, oral administration, HTT protein target - Read more

THE GOOD
Company Launches

Aditum launches Kalexo Bio with Mabwell siRNA asset, pays $12M upfront in deal worth up to $1B for cardiovascular drug
Licensing deal, cardiovascular disease, siRNA, R&D, milestone payments, equity investment - Read more

Ollin Biosciences launches with $100M to advance eye disease drugs, aiming to rival Roche’s Vabysmo and Amgen’s Tepezza
Ophthalmology, antibody, diabetic macular edema, age-related macular degeneration, clinical-stage - Read more

THE GOOD
Fundraises

ARTHEx Biotech raises $87M Series B for RNA medicines targeting myotonic dystrophy
Rare disease, RNA medicine, neuromuscular disorders, clinical-stage, myotonic dystrophy - Read more

Trially AI raises $4.7M Seed for AI-powered clinical trial recruitment platform
Clinical trial platform, AI/ML platform, healthcare software, data analytics, services - Read more

AltrixBio raises $5M Series A for oral therapy targeting cardiometabolic diseases
Cardiometabolic disease, type 2 diabetes, oral therapy, preclinical, platform-enabled, metabolic diseases - Read more

RevOpsis Therapeutics receives investment from ExSight, developing novel antibody therapies for retinal diseases
Ophthalmology, retinal diseases, antibody, AMD, preclinical, platform technology - Read more

Enhanced Genomics raises $19M Series A, 3D multi-omics platform targeting autoimmune diseases
Platform technology, autoimmune, 3D multi-omics, drug target discovery, AI-driven - Read more

Cytokinetics raises $550M in convertible notes to fund aficamten commercialization and pipeline development
Cardiovascular, small molecule, clinical-stage, drug discovery - Read more

PRESENTED BY YOU?
Get the attention of 2200+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Clinical Trials

AstraZeneca's Fasenra fails Ph3 RESOLUTE trial for chronic obstructive pulmonary disease, missing exacerbation reduction endpoint
Antibody, respiratory disease, monoclonal antibody, COPD, eosinophilic inflammation, IL-5 targeting - Read more

THE BAD
Layoffs

Novo Nordisk cuts 263 jobs in New Jersey amid global restructuring; BMS eliminates 282 positions
Layoffs, operational, cost reduction, financial, strategic - Read more

X4 Pharmaceuticals cuts workforce by 50% to save $13M annually while completing Xolremdi phase 3 trial
Small molecule, neutropenia, cost reduction, operational, clinical trial - Read more

ArsenalBio cuts 50% of workforce in strategic shift to clinical-stage company; maintains Bristol Myers Squibb partnership
CAR-T cell therapy, oncology, strategic restructuring, workforce reduction, clinical pipeline prioritization - Read more

Innate Pharma cuts 30% of staff, narrows focus to three key assets amid funding challenges
Antibody-drug conjugate (ADC), oncology, monoclonal antibody, financial, cost reduction, strategic - Read more

THE UGLY
Politics & Policy

RFK Jr. fired CDC director after demanding evidence-free vaccine policy changes, Senate testimony reveals
Vaccines, infectious disease, regulatory, policy - Read more

Former CDC director Monarez claims RFK Jr. plans to alter childhood vaccine schedule without scientific basis
Vaccines, infectious disease, regulatory, policy - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here